Peter L. Buzy, President, Gene Therapy at Catalent, Inc. (CTLT), bought 44,500 shares at $45.13 ($2.0M) on 2019-05-29, disclosed to the SEC on 2019-05-30.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Negative factors outweigh the positive ones.
| Filing → |